Climb Bio Stock Market Value
| CLYM Stock | 1.95 0.08 3.94% |
| Symbol | Climb |
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Climb Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Climb Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Climb Bio.
| 11/21/2024 |
| 12/21/2024 |
If you would invest 0.00 in Climb Bio on November 21, 2024 and sell it all today you would earn a total of 0.00 from holding Climb Bio or generate 0.0% return on investment in Climb Bio over 30 days. Climb Bio is related to or competes with Dogwood Therapeutics,, Opus Genetics,, and Telix Pharmaceuticals. Climb Bio is entity of United States. It is traded as Stock on NASDAQ exchange. More
Climb Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Climb Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Climb Bio upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.40) | |||
| Maximum Drawdown | 20.92 | |||
| Value At Risk | (9.49) | |||
| Potential Upside | 5.92 |
Climb Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Climb Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Climb Bio's standard deviation. In reality, there are many statistical measures that can use Climb Bio historical prices to predict the future Climb Bio's volatility.| Risk Adjusted Performance | (0.30) | |||
| Jensen Alpha | (2.00) | |||
| Total Risk Alpha | (2.13) | |||
| Treynor Ratio | (10.01) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Climb Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Climb Bio Backtested Returns
Climb Bio secures Sharpe Ratio (or Efficiency) of -0.4, which signifies that the company had a -0.4% return per unit of risk over the last 3 months. Climb Bio exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Climb Bio's Standard Deviation of 5.03, mean deviation of 3.91, and Risk Adjusted Performance of (0.30) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.2, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Climb Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Climb Bio is expected to be smaller as well. At this point, Climb Bio has a negative expected return of -1.98%. Please make sure to confirm Climb Bio's maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Climb Bio performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.10 |
Insignificant predictability
Climb Bio has insignificant predictability. Overlapping area represents the amount of predictability between Climb Bio time series from 21st of November 2024 to 6th of December 2024 and 6th of December 2024 to 21st of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Climb Bio price movement. The serial correlation of 0.1 indicates that less than 10.0% of current Climb Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.1 | |
| Spearman Rank Test | -0.15 | |
| Residual Average | 0.0 | |
| Price Variance | 0.21 |
Climb Bio lagged returns against current returns
Autocorrelation, which is Climb Bio stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Climb Bio's stock expected returns. We can calculate the autocorrelation of Climb Bio returns to help us make a trade decision. For example, suppose you find that Climb Bio has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Climb Bio regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Climb Bio stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Climb Bio stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Climb Bio stock over time.
Current vs Lagged Prices |
| Timeline |
Climb Bio Lagged Returns
When evaluating Climb Bio's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Climb Bio stock have on its future price. Climb Bio autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Climb Bio autocorrelation shows the relationship between Climb Bio stock current value and its past values and can show if there is a momentum factor associated with investing in Climb Bio.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Climb Bio Correlation, Climb Bio Volatility and Climb Bio Alpha and Beta module to complement your research on Climb Bio. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Climb Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.